Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.36 |
| ▸ | GGT1 | P19440 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10230791 | 1.00 | NOD1 (0.43) | NOD1EPHX2ITGB3ITGA2BFOLH1 | |
| SCHEMBL12226550 | 0.90 | NOD1 (0.50) | NOD1EPHX2ITGB3ITGA2BFOLH1 | |
| SCHEMBL6268494 | 0.88 | NOD1 (0.50) | NOD1EPHX2ITGB3ITGA2BMMP2 | |
| SCHEMBL10230794 | 0.84 | EPHX1 (0.37) | NOD1EPHX2ENPEP | |
| SCHEMBL10230776 | 0.84 | EPHX1 (0.37) | NOD1EPHX2ENPEP | |
| SCHEMBL29198010 | 0.84 | NOD1 (0.55) | NOD1ITGB3ITGA2BGGT1CHRM1 | |
| SCHEMBL10278088 | 0.83 | LMNA (0.42) | FOLH1CA2 | |
| SCHEMBL10278171 | 0.83 | LMNA (0.42) | FOLH1CA2 | |
| SCHEMBL28862007 | 0.82 | NOD1 (0.57) | NOD1ITGB3ITGA2B | |
| Methane SCHEMBL28164645 | 0.82 | NOD1 (0.54) | NOD1ITGB3ITGA2BGGT1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | NOD1 877/4885EPHX2 678/4885ITGB3 3213/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | NOD1 877/4885EPHX2 678/4885ITGB3 3213/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | NOD1 832/4885EPHX2 660/4885ITGB3 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.